-
Gracell Biotechnologies’ GC012F Showcases Positive Data at ASCO Annual Meeting
•
Suzhou-based biotech firm Gracell Biotechnologies Inc., (Nasdaq: GRCL) has announced positive data for its pipeline candidate GC012F at the American Society of Clinical Oncology (ASCO) Annual Meeting. GC012F is a FasTCAR-T therapy targeting both B-cell maturation antigen (BCMA) and CD19, under development for the treatment of relapsed/refractory multiple myeloma (r/r…
-
Biosyngen’s BRG01 Earns Orphan Drug Designation from US FDA for Nasopharyngeal Carcinoma
•
Biosyngen, a leading cell therapy developer based in Guangzhou, has announced that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its first-in-class nasopharyngeal carcinoma (NPC) cell therapy, BRG01. BRG01: A Pioneering Cell Therapy for NPCBRG01 is a genetically modified T cell product…
-
NMPA Grants Market Approval for Lanzhou Kejin Taiji’s Carbon Ion Therapy System
•
The National Medical Products Administration (NMPA) in China has issued market approval to Lanzhou Kejin Taiji Corporation, Ltd. for its carbon ion therapy system, marking it as the second home-grown carbon ion therapy system in the country designed for the treatment of malignant solid tumors. Enhanced Features of the New…
-
Innovent Biologics Partners with Merck KGaA to Test KRAS Inhibitor Combo in NSCLC
•
China-based Innovent Biologics (HKG: 1801) has announced a clinical study and supply agreement with German pharmaceutical giant Merck KGaA (NYSE: MRK). The collaboration aims to explore the combination of Innovent’s KRAS G12C inhibitor, IBI351, and Merck’s Erbitux (cetuximab) in patients with advanced non-small cell lung cancer (NSCLC) harboring the KRAS…
-
Shenzhen Abrobo Medical Robot Secures RMB 100 Million in Series A Financing for Robotic Development
•
Shenzhen Abrobo Medical Robot Co, Ltd has reportedly raised RMB 100 million via a Series A financing round, marking a significant step forward for the company. The round was led by Guozhong Capital, with additional investments from Lenovo Capital and Long Hill Capital. The funds will be directed towards accelerating…
-
Coherus and Junshi Biosciences Await FDA Decision on Toripalimab After Inspection
•
US-based Coherus Biosciences Inc., (NASDAQ: CHRS) has disclosed that the US FDA has recently completed the long-awaited pre-licensing inspection of its partner Junshi Biosciences Ltd’s (HKG: 1877, SHA: 688180) manufacturing site for toripalimab in China. The inspection resulted in “three observations” from the FDA, which Coherus described as “readily addressable.”…
-
Betta Pharmaceuticals’ Befotertinib Approved by China’s NMPA for EGFR-Mutated NSCLC
•
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced receiving market approval from the National Medical Products Administration (NMPA) for its third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), befotertinib, for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with the EGFR T790M mutation that has…
-
Antengene’s Xpovio Combination Therapy Approved for Reimbursement in Australia for R/R MM
•
China-based biotech Antengene Corp., Ltd (HKG: 6996) has revealed that Australia’s Pharmaceutical Benefits Scheme (PBS) will reimburse the firm’s Xpovio (selinexor) plus bortezomib and dexamethasone combination therapy for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM), specifically for those who have previously received one other therapy. This…
-
HighField Biopharmaceuticals Presents Promising HF1K16 Data at ASCO Annual Meeting
•
Hangzhou-based biotech HighField Biopharmaceuticals has revealed the publication of an abstract at this year’s American Society of Clinical Oncology (ASCO) annual meeting, showcasing preliminary data from a Phase Ia trial for its lead pipeline candidate, HF1K16. The trial, which focused on refractory metastatic cancer patients, indicated that HF1K16 was well…
-
BeiGene’s Brukinsa Receives Canadian Approval for Chronic Lymphocytic Leukemia
•
China-based BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor, Brukinsa (zanubrutinib), has received the latest indication approval in Canada for the treatment of chronic lymphocytic leukemia (CLL). This approval marks the fourth total approved Canadian indication for Brukinsa, following earlier approvals…
-
Sanofi’s Commitment to China: Expansion, Digital Innovation, and Local R&D
•
Wayne Shi, president of France-based Sanofi’s (NASDAQ: SNY) Greater China business, has been discussing the firm’s ongoing commitment to the China market with local media. Speaking to China Daily, Shi emphasized that Sanofi has “always been optimistic about the Chinese market and will continuously expand our investment in China.” Sanofi…
-
Chia Tai Tianqing’s Biosimilar Rituximab Approved by China’s NMPA for Lymphoma Treatments
•
China-based Chia Tai Tianqing has announced receiving a market approval from the National Medical Products Administration (NMPA) for its biosimilar version of Roche’s MabThera (rituximab), which is used for the treatment of follicular lymphoma (FL), CD20 positive diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL). Phase III Study…
-
Galvanize Therapeutics Partners with Energenx Medical for Greater China Expansion
•
US-based Galvanize Therapeutics Inc. has revealed a licensing deal with Shanghai-based Energenx Medical Ltd, which will see Energenx develop and commercialize Galvanize’s products in Greater China, including Hong Kong, Taiwan, and Macau. Financial details of the agreement have not been disclosed. Energenx was established by Galvanize in collaboration with founding…
-
AstraZeneca Launches Calquence in China for Mantle Cell Lymphoma Treatment
•
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced the official market launch of Calquence (acalabrutinib), a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, in China. The drug previously received conditional marketing approval in the country in March this year, specifically for the treatment of mantle cell lymphoma (MCL) that has…
-
Hisun Pharmaceutical’s SHP2 Inhibitor HS336 Gets NMPA Clinical Trial Approval
•
Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a China-based pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug HS336, intended for the treatment of advanced solid tumors. HS336: A Novel SHP2 Inhibitor for Anti-Tumor TherapyHS336 is a…
-
Harbour Biomed’s Porustobart Combo Shows Promise in HCC Treatment, ASCO Presentation Reveals
•
China-based Harbour Biomed (HKG: 2142) has announced the publication of results from a Phase Ib clinical study of its CTLA-4 antibody porustobart (HBM4003) in combination with Junshi Biosciences’ (HKG: 1877, SHA: 688180) PD-1 inhibitor toripalimab for the treatment of hepatocellular carcinoma (HCC) at the American Society of Clinical Oncology (ASCO)…
-
Ascentage Pharma’s Olverembatinib Earns Breakthrough Designation for SDH-Deficient GIST
•
The China’s Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) to olverembatinib, a Category 1 drug developed by Suzhou Ascentage Pharma Co., Ltd’s (HKG: 6855) wholly-owned subsidiary, Guangzhou Shunjian Biopharmaceutical Technology Co., Ltd. The designation targets succinate dehydrogenase (SDH) deficient gastrointestinal stromal tumors (GIST) that have received…
-
Abbisko Therapeutics Reports Positive Phase Ib Results for ABSK021 at ASCO
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) is poised to announce positive results from a Phase Ib clinical study of its drug ABSK021 (pimicotinib) in the treatment of tenosynovial giant cell tumor (TGCT) at the American Society of Clinical Oncology (ASCO) annual meeting. Impressive Objective Response Rates for PimicotinibThe…
-
Shanghai Yizhong’s Paclitaxel Micelles Data to be Presented at ASCO Annual Meeting
•
Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091), a China-based pharmaceutical company, has announced that clinical data for its paclitaxel polymer micelles will be presented at the prestigious American Society of Clinical Oncology (ASCO) annual meeting. Clinical Data from Retrospective Study in NSCLC TreatmentThe data originates from a retrospective study examining…
-
Ascentage Pharma to Present Clinical Results of Four Oncology Drugs at Medical Conference
•
Suzhou-based Ascentage Pharma (HKG: 6855) has announced its intention to present the clinical results of its four oncology drugs, including olverembatinib, Bcl-2 inhibitor APG-2575, MDM2-p53 inhibitor APG-115, and FAK/ALK/ROS1 triple inhibitor APG-2449, at an upcoming medical conference. Phase I Study for APG-2449 in Solid TumorsAn open, multicenter, dose escalation, and…
